FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088579900> ?p ?o ?g. }

• W3088579900 endingPage "4188" @default.
• W3088579900 startingPage "4180" @default.
• W3088579900 abstract "Targeted α particle therapy (TAT) is ideal for treating disease while minimizing damage to surrounding nontargeted tissues due to short path length and high linear energy transfer (LET). We developed a TAT for metastatic uveal melanoma, targeting the melanocortin-1 receptor (MC1R), which is expressed in 94% of uveal melanomas. Two versions of the therapy are being investigated: 225Ac-DOTA-Ahx-MC1RL (225Ac-Ahx) and 225Ac-DOTA-di-d-Glu-MC1RL (225Ac-di-d-Glu). The biodistribution (BD) from each was studied and a multicompartment pharmacokinetic (PK) model was developed to describe drug distribution rates. Two groups of 16 severe combined immunodeficient (SCID) mice bearing high MC1R expressing tumors were intravenously injected with 225Ac-Ahx or 225Ac-di-d-Glu. After injection, four groups (n = 4) were euthanized at 24, 96, 144, and 288 h time points for each cohort. Tumors and 13 other organs were harvested at each time point. Isomeric γ spectra were measured in tissue samples using a scintillation γ detector and converted to α activity using factors for γ ray abundance per α decay. Time activity curves were calculated for each organ. A five-compartment PK model was built with the following compartments: blood, tumor, normal tissue, kidney, and liver. This model is characterized by a system of five ordinary differential equations using mass action kinetics, which describe uptake, intercompartmental transitions, and clearance rates. The ordinary differential equations were simultaneously solved and fit to experimental data using a genetic algorithm for optimization. The BD data show that both compounds have minimal distribution to organs at risk other than the kidney and liver. The PK parameter estimates had less than 5% error. From these data, 225Ac-Ahx showed larger and faster uptake in the liver. Both compounds had comparable uptake and clearance rates for other compartments. The BD and PK behavior for two targeted radiopharmaceuticals were investigated. The PK model fit the experimental data and provided insight into the kinetics of the compounds systematically." @default.
• W3088579900 created "2020-10-01" @default.
• W3088579900 creator A5000946019 @default.
• W3088579900 creator A5015266743 @default.
• W3088579900 creator A5016797428 @default.
• W3088579900 creator A5021689808 @default.
• W3088579900 creator A5027847163 @default.
• W3088579900 creator A5027944218 @default.
• W3088579900 creator A5038597614 @default.
• W3088579900 creator A5052398157 @default.
• W3088579900 creator A5065959120 @default.
• W3088579900 creator A5066706584 @default.
• W3088579900 creator A5078431028 @default.
• W3088579900 creator A5088125906 @default.
• W3088579900 date "2020-09-22" @default.
• W3088579900 modified "2023-10-14" @default.
• W3088579900 title "Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy" @default.
• W3088579900 cites W1970051943 @default.
• W3088579900 cites W1987786460 @default.
• W3088579900 cites W1988809239 @default.
• W3088579900 cites W1995835470 @default.
• W3088579900 cites W2013374137 @default.
• W3088579900 cites W2018649196 @default.
• W3088579900 cites W2022537633 @default.
• W3088579900 cites W2042028934 @default.
• W3088579900 cites W2044515851 @default.
• W3088579900 cites W2070327519 @default.
• W3088579900 cites W2071761375 @default.
• W3088579900 cites W2080147734 @default.
• W3088579900 cites W2080489673 @default.
• W3088579900 cites W2082375360 @default.
• W3088579900 cites W2131043862 @default.
• W3088579900 cites W2136339951 @default.
• W3088579900 cites W2149171028 @default.
• W3088579900 cites W2166477438 @default.
• W3088579900 cites W2181186324 @default.
• W3088579900 cites W2261199191 @default.
• W3088579900 cites W2329160789 @default.
• W3088579900 cites W2596182791 @default.
• W3088579900 cites W2808551116 @default.
• W3088579900 cites W2891647981 @default.
• W3088579900 cites W2913066485 @default.
• W3088579900 cites W2962799181 @default.
• W3088579900 cites W4244370284 @default.
• W3088579900 cites W65135050 @default.
• W3088579900 doi "https://doi.org/10.1021/acs.molpharmaceut.0c00640" @default.
• W3088579900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32960613" @default.
• W3088579900 hasPublicationYear "2020" @default.
• W3088579900 type Work @default.
• W3088579900 sameAs 3088579900 @default.
• W3088579900 citedByCount "3" @default.
• W3088579900 countsByYear W30885799002021 @default.
• W3088579900 countsByYear W30885799002023 @default.
• W3088579900 crossrefType "journal-article" @default.
• W3088579900 hasAuthorship W3088579900A5000946019 @default.
• W3088579900 hasAuthorship W3088579900A5015266743 @default.
• W3088579900 hasAuthorship W3088579900A5016797428 @default.
• W3088579900 hasAuthorship W3088579900A5021689808 @default.
• W3088579900 hasAuthorship W3088579900A5027847163 @default.
• W3088579900 hasAuthorship W3088579900A5027944218 @default.
• W3088579900 hasAuthorship W3088579900A5038597614 @default.
• W3088579900 hasAuthorship W3088579900A5052398157 @default.
• W3088579900 hasAuthorship W3088579900A5065959120 @default.
• W3088579900 hasAuthorship W3088579900A5066706584 @default.
• W3088579900 hasAuthorship W3088579900A5078431028 @default.
• W3088579900 hasAuthorship W3088579900A5088125906 @default.
• W3088579900 hasConcept C110121322 @default.
• W3088579900 hasConcept C112705442 @default.
• W3088579900 hasConcept C126322002 @default.
• W3088579900 hasConcept C134306372 @default.
• W3088579900 hasConcept C178790620 @default.
• W3088579900 hasConcept C185592680 @default.
• W3088579900 hasConcept C197404232 @default.
• W3088579900 hasConcept C202751555 @default.
• W3088579900 hasConcept C2777658100 @default.
• W3088579900 hasConcept C2777807558 @default.
• W3088579900 hasConcept C2779931791 @default.
• W3088579900 hasConcept C2780091579 @default.
• W3088579900 hasConcept C2989005 @default.
• W3088579900 hasConcept C2993559085 @default.
• W3088579900 hasConcept C33923547 @default.
• W3088579900 hasConcept C502942594 @default.
• W3088579900 hasConcept C55493867 @default.
• W3088579900 hasConcept C71924100 @default.
• W3088579900 hasConcept C98274493 @default.
• W3088579900 hasConceptScore W3088579900C110121322 @default.
• W3088579900 hasConceptScore W3088579900C112705442 @default.
• W3088579900 hasConceptScore W3088579900C126322002 @default.
• W3088579900 hasConceptScore W3088579900C134306372 @default.
• W3088579900 hasConceptScore W3088579900C178790620 @default.
• W3088579900 hasConceptScore W3088579900C185592680 @default.
• W3088579900 hasConceptScore W3088579900C197404232 @default.
• W3088579900 hasConceptScore W3088579900C202751555 @default.
• W3088579900 hasConceptScore W3088579900C2777658100 @default.
• W3088579900 hasConceptScore W3088579900C2777807558 @default.
• W3088579900 hasConceptScore W3088579900C2779931791 @default.
• W3088579900 hasConceptScore W3088579900C2780091579 @default.
• W3088579900 hasConceptScore W3088579900C2989005 @default.

• next